Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-03. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Shortly afterwards, the US VII Corps, in full strength and spearheaded by the 2nd Armored Cavalry Regiment, launched an armored attack into Iraq early on 24 February, just to the west of Kuwait, surprising Iraqi forces. Simultaneously, the US XVIII Airborne Corps launched a sweeping "left-hook" attack across southern Iraq's largely undefended desert, led by the US 3rd Armored Cavalry Regiment and the 24th Infantry Division (Mechanized). This movement's left flank was protected by the French Division Daguet. The 101st Airborne Division conducted a combat air assault into enemy territory. The 101st Airborne Division had struck 249 km (155 mi) behind enemy lines. It was the deepest air assault operation in history. Approximately 400 helicopters transported 2,000 soldiers into Iraq where they destroyed Iraqi columns trying to flee westward and prevented the escape of Iraqi forces. The 101st Airborne Division travelled a further 80 to 100 km (50 to 60 mi) into Iraq. By nightfall, the 101st cut off Highway 8 which was a vital supply line running between Basra and the Iraqi forces. The 101st had lost 16 soldiers in action during the 100-hour war and captured thousands of enemy prisoners of war. The French force quickly overcame Iraq's 45th Infantry Division, suffering light casualties and taking a large number of prisoners, and took up blocking positions to prevent an Iraqi counterattack on the coalition's flank. The movement's right flank was protected by the United Kingdom's 1st Armoured Division.
=== Applications === The enhanced sensitivity of eSimoa is crucial for early and accurate biomarker detection in clinical diagnostics, facilitating better disease monitoring and management. In drug discovery, the ability to track subtle changes in enzymatic activity aids in the development of more effective pharmaceuticals by providing detailed insights into enzyme inhibition mechanisms.
== References == Chan, E.W.C; S.K. Wong (2009). "Chemical constituents of leaves of Rhizophora x lamarckii, R. apiculata and R. stylosa" (PDF). ISME/GLOMIS Electronic Journal. 7 (1): 1–2. Chan, H.T. (1996). "A note on the discovery of Rhizophora x lamarckii in Peninsular Malaysia" (PDF). Journal of Tropical Forest Science. 9: 128–130. Duke, N.C. (2006). “Australia’s Mangroves: The Authoritative Guide to Australia’s Mangrove Plants”. University of Queensland, Brisbane, 200 p. ISBN 0-646-46196-6. Tomlinson, P.B. (1986). “The Botany of Mangroves”. Cambridge University Press, 413 p. ISBN 0-521-25567-8.
In the 1980s, Wächtershäuser and Karl Popper postulated the iron–sulfur world hypothesis for the evolution of pre-biotic chemical pathways. It traces today's biochemistry to primordial reactions which synthesize organic building blocks from gases. Wächtershäuser systems have a built-in source of energy: iron sulfides such as pyrite. The energy released by oxidising these metal sulfides can support synthesis of organic molecules. Such systems may have evolved into autocatalytic sets constituting self-replicating, metabolically active entities predating modern life forms. Experiments with sulfides in an aqueous environment at 100 °C produced a small yield of dipeptides (0.4% to 12.4%) and a smaller yield of tripeptides (0.10%). However, under the same conditions, dipeptides were quickly broken down. Several models postulate a primitive metabolism, allowing RNA replication to emerge later. The centrality of the Krebs cycle (citric acid cycle) to energy production in aerobic organisms, and in drawing in carbon dioxide and hydrogen ions in biosynthesis of complex organic chemicals, suggests that it was one of the first parts of the metabolism to evolve. Concordantly, geochemists Szostak and Kate Adamala demonstrated that non-enzymatic RNA replication in primitive protocells is only possible in the presence of weak cation chelators like citric acid. This provides further evidence for the central role of citric acid in primordial metabolism.
Sources: en.wikipedia.org
Senegal: Foreign Minister Cheikh Niang held a phone call with Venezuelan Foreign Minister Yván Gil, expressing solidarity to the Venezuelan people and Senegal's commitment to international law, supporting the principle of non-intervention, and the right of Venezuelans to determine their own future. Somaliland: The Ministry of Foreign Affairs announced its support for the operation and stated that Somaliland believes that it can lead to a "peaceful, Venezuelan-led political transition". South Africa: The Department of International Relations released a press statement which viewed the US' actions "as a manifest violation of the Charter of the United Nations". The Charter "does not authorise external military intervention in matters that are essentially within the domestic jurisdiction of a sovereign nation", and South Africa pointed to history to demonstrate how "military invasions against sovereign states yield only instability and deepening crisis". It, furthermore, called on the United Nations Security Council (UNSC) to urgently convene to address the situation. Uganda: President Yoweri Museveni did not explicitly support or condemn the strikes, instead commenting on the military strategy during a youth forum on 4 January, stating he didn't know what they were fighting for but that he was "still studying it".
Additionally, criminal organizations work together to coordinate money-laundering activities by having separate organizations handle specific stages of laundering process. One organization structures the process of how financial transactions will be laundered, while another criminal group provides the "dirty" money to be cleaned. By fostering expansion of trade and global transportation networks, free trade encourages cooperation and formation of alliances among criminal organizations across different countries. The drug trade in Latin America emerged in the early 1930s. It saw significant growth in the Andean countries, including Peru, Bolivia, Chile, Ecuador, Colombia and Venezuela. The underground market in the early half of the 20th century mainly had ties to Europe. After World War II, the Andean countries saw an expansion of trade, specifically with cocaine.
This is about 17% of the terrestrial ratio of 156 deuterium atoms per million hydrogen atoms. Comets such as Comet Hale–Bopp and Halley's Comet have been measured to contain more deuterium (about 200 atoms per million hydrogens), ratios which are enriched with respect to the presumed protosolar nebula ratio, probably due to heating, and which are similar to the ratios found in Earth seawater. The recent measurement of deuterium amounts of 161 atoms per million hydrogen in Comet 103P/Hartley (a former Kuiper belt object), a ratio almost exactly that in Earth's oceans (155.76 ± 0.1, but in fact from 153 to 156 ppm), emphasizes the theory that Earth's surface water may be largely from comets. Most recently the 2H1HR of 67P/Churyumov–Gerasimenko as measured by Rosetta is about three times that of Earth water. This has caused renewed interest in suggestions that Earth's water may be partly of asteroidal origin. Deuterium has also been observed to be concentrated over the mean solar abundance in other terrestrial planets, in particular Mars and Venus.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.